Radiosensitization of prostate cancer cells with adenoviral p53 gene therapy was independent of the status of p53, as the sensitization is seen in both the p53 (wild-type) human prostate cancer cell LNCaP and p53 (null) PC-3 lines[90]. This evidence concerns the gene TP53 and prostate carcinoma.